Keros Therapeutics (KROS) Revenue & Revenue Breakdown
Keros Therapeutics Revenue Highlights
Latest Revenue (Y)
$3.55M
Latest Revenue (Q)
$18.17M
Main Segment (Y)
License
Keros Therapeutics Revenue by Period
Keros Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $3.55M | 2250.99% |
| 2023-12-31 | $151.00K | 100.00% |
| 2022-12-31 | - | -100.00% |
| 2021-12-31 | $20.10M | 100.00% |
| 2020-12-31 | - | -100.00% |
| 2019-12-31 | $10.00M | - |
| 2018-12-31 | $10.00M | - |
Keros Therapeutics generated $3.55M in revenue during NA 2024, up 2250.99% compared to the previous quarter, and up 35.50% compared to the same period a year ago.
Keros Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $18.17M | -91.40% |
| 2025-03-31 | $211.25M | 6844.31% |
| 2024-12-31 | $3.04M | 684.02% |
| 2024-09-30 | $388.00K | 948.65% |
| 2024-06-30 | $37.00K | -55.42% |
| 2024-03-31 | $83.00K | -41.96% |
| 2023-12-31 | $143.00K | 1687.50% |
| 2023-09-30 | $8.00K | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | -100.00% |
| 2022-06-30 | $100.00K | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $20.00M | 100.00% |
| 2021-09-30 | - | -100.00% |
| 2021-06-30 | $100.00K | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | -100.00% |
| 2019-12-31 | $2.50M | - |
| 2019-09-30 | $2.50M | - |
| 2019-06-30 | $2.50M | - |
| 2019-03-31 | $2.50M | - |
Keros Therapeutics generated $18.17M in revenue during Q2 2025, up -91.40% compared to the previous quarter, and up 21889.16% compared to the same period a year ago.
Keros Therapeutics Revenue Breakdown
Keros Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 22 | Dec 21 |
|---|---|---|---|
| Service | $3.00M | - | - |
| License | $144.00M | $144.00M | $144.00M |
Latest
Keros Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: License (97.96%), and Service (2.04%).
Quarterly Revenue by Product
| Product/Service | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License | $10.00M | $195.35M | $144.00M | $144.00M | $144.00M | $144.00M | $18.00M | $20.00M | $100.00K | - | - | - | - |
| Service, Other | $4.26M | $18.17M | $15.89M | $83.00K | - | - | - | - | - | - | - | - | - |
| Service | - | - | - | $2.60M | $400.00K | - | - | - | - | - | - | - | - |
Latest
Keros Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: License (70.12%), and Service, Other (29.88%).
Keros Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RIGL | Rigel Pharmaceuticals | $179.28M | $69.46M |
| CTMX | CytomX Therapeutics | $138.10M | $18.66M |
| NAGE | Niagen Bioscience | $99.60M | $29.13M |
| RGNX | REGENXBIO | $83.33M | $29.73M |
| VSTM | Verastem | $10.00M | $11.24M |
| ABSI | Absci | $4.53M | $378.00K |
| KROS | Keros Therapeutics | $3.55M | $18.17M |
| CRVS | Corvus Pharmaceuticals | - | - |
| VTYX | Ventyx Biosciences | - | - |
| MLTX | MoonLake Immunotherapeutics | - | - |
| OLMA | Olema Pharmaceuticals | - | - |